Lifevantage (NASDAQ:LFVN) Stock Rating Lowered by Wall Street Zen

Lifevantage (NASDAQ:LFVN) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

LFVN has been the topic of a number of other reports. Lake Street Capital reissued a “buy” rating and issued a $12.00 price target on shares of Lifevantage in a research note on Wednesday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Lifevantage in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $23.50.

Lifevantage Stock Up 9.6%

Shares of Lifevantage stock opened at $7.40 on Friday. The firm has a market cap of $93.91 million, a PE ratio of 10.00 and a beta of 0.22. Lifevantage has a 52 week low of $6.60 and a 52 week high of $27.38. The business’s fifty day simple moving average is $9.77 and its 200-day simple moving average is $11.75.

Lifevantage (NASDAQ:LFVN) last issued its quarterly earnings data on Tuesday, November 4th. The company reported $0.18 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.17 by $0.01. Lifevantage had a return on equity of 33.75% and a net margin of 4.29%.The firm had revenue of $47.56 million during the quarter, compared to the consensus estimate of $54.74 million. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Insider Activity at Lifevantage

In other news, Director Michael A. Beindorff sold 4,125 shares of the company’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $11.44, for a total transaction of $47,190.00. Following the sale, the director owned 22,858 shares of the company’s stock, valued at approximately $261,495.52. This represents a 15.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 21.95% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LFVN. Trexquant Investment LP acquired a new stake in Lifevantage in the first quarter valued at approximately $1,607,000. Acadian Asset Management LLC increased its position in shares of Lifevantage by 47.3% in the 1st quarter. Acadian Asset Management LLC now owns 291,700 shares of the company’s stock valued at $4,248,000 after purchasing an additional 93,661 shares during the last quarter. Core Wealth Partners LLC acquired a new stake in shares of Lifevantage in the 1st quarter valued at $480,000. Cambridge Investment Research Advisors Inc. lifted its position in shares of Lifevantage by 23.2% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 12,867 shares of the company’s stock worth $188,000 after purchasing an additional 2,421 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Lifevantage by 28.1% during the 1st quarter. American Century Companies Inc. now owns 122,428 shares of the company’s stock worth $1,785,000 after purchasing an additional 26,876 shares during the last quarter. 35.32% of the stock is currently owned by hedge funds and other institutional investors.

About Lifevantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.